Precigen, Inc. (NASDAQ:PGEN) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Precigen, Inc. (NASDAQ:PGEN) have earned a consensus rating of “Moderate Buy” from the six research firms that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating, three have given a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $14.50.

Several analysts have recently issued reports on PGEN shares. Citigroup reissued an “outperform” rating on shares of Precigen in a research note on Thursday, May 14th. Citizens Jmp boosted their price target on Precigen from $9.00 to $11.00 and gave the company a “market outperform” rating in a research report on Thursday, May 14th. Zacks Research upgraded Precigen from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, August 5th. Wall Street Zen upgraded Precigen from a “hold” rating to a “strong-buy” rating in a report on Saturday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Precigen in a research report on Friday, July 17th.

Precigen Trading Down 3.2%

Shares of PGEN stock opened at $7.00 on Tuesday. The firm’s 50-day simple moving average is $5.29 and its 200-day simple moving average is $4.52. The company has a debt-to-equity ratio of 2.15, a current ratio of 4.58 and a quick ratio of 3.89. Precigen has a 1-year low of $1.70 and a 1-year high of $7.32. The firm has a market cap of $2.50 billion, a P/E ratio of -6.73 and a beta of 1.02.

Precigen (NASDAQ:PGEN) last released its earnings results on Tuesday, August 4th. The biotechnology company reported $0.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.06. The firm had revenue of $54.98 million during the quarter, compared to the consensus estimate of $27.98 million. Precigen had a negative net margin of 183.98% and a positive return on equity of 423.75%. Precigen’s revenue was up 6322.7% on a year-over-year basis. As a group, equities analysts forecast that Precigen will post 0.05 EPS for the current year.

Insider Buying and Selling at Precigen

In related news, COO Rutul R. Shah sold 32,739 shares of the company’s stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $6.86, for a total transaction of $224,589.54. Following the completion of the sale, the chief operating officer directly owned 465,012 shares of the company’s stock, valued at approximately $3,189,982.32. This represents a 6.58% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Harry Jr. Thomasian sold 100,000 shares of the stock in a transaction on Friday, July 31st. The shares were sold at an average price of $6.06, for a total value of $606,000.00. Following the completion of the sale, the chief financial officer owned 254,535 shares of the company’s stock, valued at approximately $1,542,482.10. This represents a 28.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 989,239 shares of company stock valued at $5,472,960 in the last ninety days. Corporate insiders own 41.40% of the company’s stock.

Institutional Investors Weigh In On Precigen

Institutional investors and hedge funds have recently modified their holdings of the stock. State of Wyoming purchased a new stake in shares of Precigen during the 1st quarter valued at about $27,000. NBC Securities Inc. purchased a new position in Precigen in the 4th quarter worth approximately $38,000. Caitong International Asset Management Co. Ltd purchased a new position in Precigen in the 3rd quarter worth approximately $39,000. Royal Bank of Canada grew its position in Precigen by 102.6% in the first quarter. Royal Bank of Canada now owns 10,714 shares of the biotechnology company’s stock valued at $41,000 after acquiring an additional 5,426 shares in the last quarter. Finally, Russell Investments Group Ltd. acquired a new stake in Precigen in the third quarter valued at approximately $41,000. Hedge funds and other institutional investors own 33.51% of the company’s stock.

Precigen Company Profile

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.